Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Next Previous
X
Search
Trial Profile

Open-Label Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Adverse reactions; Registrational
  • Sponsors SK Life Science

    • Most Recent Events

    • 11 Apr 2024 According to a SK Life Science media release, based on data from this study, U.S. Food and Drug Administration approved two new administration options of cenobamate tablets an antiseizure medication for adults with partial onset (focal) seizures, which can now be crushed and mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube.
    • 23 Mar 2023 Status changed from active, no longer recruiting to recruiting.
    • 20 Dec 2022 Planned End Date changed from 1 Sep 2024 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top